Zoghbi Huda Y reported option exercise involving 7,439 shares of REGENERON PHARMACEUTICALS, INC. at $380.95 for $2.83M on Nov 3, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Nov 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$2,833,887.05Shares × reported price
Shares traded
7,439Common Stock
Price per share
$380.95Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
9,142Direct
Trade date
Nov 3, 2026Option exercise
Filed
Nov 5, 2026, 4:05 PM ET2-day reporting delay
Accession
0001681643-26-000008Code M · Transaction 393367
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 3, 2026Option exercise7,439$0.00$0Trade 393370
Nov 3, 2026Sell6,939$970.42−$6,733,744.38Trade 393368
Nov 3, 2026Sell500$971.06−$485,530Trade 393369
4 transaction rows in this filing. Joint filers share the same rows.

REGN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
REGN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −19%1w ago −9.6%1d ago +6.5%
Returns since7d +6.3%30d90d180d1y

Footnotes in full

F1: Represents volume-weighted average price of sales of 6,939 shares of Company stock on November 3, 2026 at prices ranging from $970.00 to $970.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 3, 2026 at each separate price. F2: Represents volume-weighted average price of sales of 500 shares of Company stock on November 3, 2026 at prices ranging from $971.00 to $971.11. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 3, 2026 at each separate price. F3: The stock option vested in three equal annual installments, commencing one year after the date of grant.